Abivax ADR (NASDAQ: ABVX) has experienced a rise in its stock price by 21.89 compared to its previous closing price of 6.35. However, the company has seen a gain of 36.03% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025.
Is It Worth Investing in Abivax ADR (NASDAQ: ABVX) Right Now?
The 36-month beta value for ABVX is also noteworthy at -0.02. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABVX is 55.60M, and at present, short sellers hold a 2.12% of that float. The average trading volume of ABVX on June 04, 2025 was 219.49K shares.
ABVX’s Market Performance
The stock of Abivax ADR (ABVX) has seen a 36.03% increase in the past week, with a 7.65% rise in the past month, and a 7.35% gain in the past quarter. The volatility ratio for the week is 8.44%, and the volatility levels for the past 30 days are at 5.72% for ABVX. The simple moving average for the past 20 days is 24.65% for ABVX’s stock, with a -5.90% simple moving average for the past 200 days.
Analysts’ Opinion of ABVX
Many brokerage firms have already submitted their reports for ABVX stocks, with Morgan Stanley repeating the rating for ABVX by listing it as a “Equal-Weight.” The predicted price for ABVX in the upcoming period, according to Morgan Stanley is $12 based on the research report published on March 20, 2025 of the current year 2025.
JMP Securities, on the other hand, stated in their research note that they expect to see ABVX reach a price target of $33. The rating they have provided for ABVX stocks is “Mkt Outperform” according to the report published on December 04th, 2024.
Laidlaw gave a rating of “Buy” to ABVX, setting the target price at $48 in the report published on July 29th of the previous year.
ABVX Trading at 22.04% from the 50-Day Moving Average
After a stumble in the market that brought ABVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.36% of loss for the given period.
Stock Fundamentals for ABVX
Current profitability levels for the company are sitting at:
- -26.32 for the present operating margin
- 0.92 for the gross margin
The net margin for Abivax ADR stands at -25.97. The total capital return value is set at -1.61. Equity return is now at value -147.48, with -66.45 for asset returns.
Based on Abivax ADR (ABVX), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -1.62. The debt to equity ratio resting at 2.37. The interest coverage ratio of the stock is -12.66.
Currently, EBITDA for the company is -171.88 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 54.25. The receivables turnover for the company is 0.43for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.82.
Conclusion
In summary, Abivax ADR (ABVX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
